8-K
filed August 31, 2023, 7:59 PM ET
ticker SCLX
CIK 0001820190
leadership
confidence high
sentiment neutral
materiality 0.85
Scilex board and CEO resign amid Oramed transaction; Dr. Lee resigns immediately
Scilex Holding Co
- Tien-Li Lee, M.D. resigned from the Board effective Aug 27, 2023, no disagreement.
- Henry Ji, Ph.D. removed as director by Sorrento's CRO; will resign as executive officer upon Oramed closing.
- CEO Jaisim Shah to retire from Board and CEO role effective upon Oramed closing.
- Directors Hamill, Followwill, Lemus resign contingent on Oramed closing (no disagreement).
- Oramed Transaction approved by Bankruptcy Court; expected close on or before Sept 30, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tien-Li Lee resigned as Director at Scilex Holding Co.
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 27, 2023, Tien-Li Lee, M.D. notified the Board of Directors (the “Board”) of the Company that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of August 27, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Lemus resigned as Director at Scilex Holding Co.
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 28, 2023, each of Dorman Followwill and David Lemus notified the Board that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dorman Followwill resigned as Director at Scilex Holding Co.
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 28, 2023, each of Dorman Followwill and David Lemus notified the Board that he was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.9
Henry Ji resigned as Executive Officer at Scilex Holding Co.
- Action
- resigned
- Role
- Executive Officer
Exact text from the filing
On August 27, 2023, Dr. Ji notified the Board that he was resigning from his position as an executive officer of the Company and any position as a director or officer of any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Henry Ji was removed as Director at Scilex Holding Co.
- Action
- removed
- Role
- Director
Exact text from the filing
On August 27, 2023, Henry Ji, Ph.D. was informed that, pursuant to Article V.E. of the Company’s Restated Certificate of Incorporation, the chief restructuring officer on behalf of Sorrento in its pending bankruptcy proceedings, as the holder of a majority in voting power of the then-outstanding shares of stock of the Company entitled to vote generally in the election of directors, had taken action by written consent to remove Dr. Ji as a director of the Company, effective as of such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Laura J. Hamill resigned as Director at Scilex Holding Co.
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 27, 2023, Laura J. Hamill notified the Board that she was resigning from the Board, all committees of the Board and any director or officer position held with any subsidiary of the Company effective as of and contingent upon the closing of the Oramed Transaction.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jaisim Shah retired as Chief Executive Officer and President at Scilex Holding Co.
- Action
- retired
- Role
- Chief Executive Officer and President
Exact text from the filing
On August 29, 2023, Jaisim Shah notified the Board that he was retiring from the Board, all committees of the Board, his position as the Chief Executive Officer and President of the Company and any position as a director or officer of any subsidiary of the Company, effective as of and contingent upon the closing of the Oramed Transaction.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.